Press Releases

2019.11.08 R&D PDF (169KB)
Daiichi Sankyo Announces Positive Results from ESAX-DN Phase 3 Study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
2019.11.05 Corporate PDF (29KB)
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
2019.10.31 R&D PDF (71KB)
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
2019.10.21 R&D PDF (186KB)
Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/ Refractory FLT3-ITD AML
2019.10.17 R&D PDF (93KB)
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer
2019.10.15 Corporate PDF (112KB)
Daiichi Sankyo Announces Transfer from Astellas Pharma of Three Products in Asia
2019.10.10 Products PDF (67KB)
Daiichi Sankyo Launches FLT3 Inhibitor VANFLYTA® in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
2019.10.08 CSR PDF (473KB)
Daiichi Sankyo Announces Installation of Onsite Solar Power System at Onahama Plant in Japan
2019.09.17 Corporate PDF (304KB)
Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil
2019.09.12 Products PDF (168KB)
Daiichi Sankyo Announces Launch of Oxycodone Extended Release Tablets NX “Daiichi Sankyo” for Sustained Cancer Pain Treatment in Japan
2019.09.10 R&D PDF (105KB)
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
2019.09.10 R&D PDF (115KB)
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
2019.09.09 R&D PDF (96KB)
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
2019.09.04 Products PDF (81KB)
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
2019.08.05 Products PDF (97KB)
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
2019.06.25 Corporate PDF (141KB)
Daiichi Sankyo to transfer marketing authorization rights for four diagnostic imaging agents in Japan to GE Healthcare
2019.06.24 R&D PDF (55KB)
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
2019.06.18 Products PDF (153KB)
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
2019.06.14 Products PDF (173KB)
Daiichi Sankyo Announces Launch of Oxycodone Injections “Daiichi Sankyo”
2019.06.03 R&D PDF (105KB)
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
2019.06.03 R&D PDF (163KB)
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
2019.05.23 Corporate PDF (94KB)
Announcement Regarding Recent Media Reports
2019.05.17 Corporate PDF (89KB)
Daiichi Sankyo Announces Update to H5N1 Influenza Vaccine National Project
2019.05.15 R&D PDF (76KB)
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
2019.05.15 R&D PDF (103KB)
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor
2019.05.13 Products PDF (193KB)
Daiichi Sankyo Launches “MINNEBRO® Tablets” in Japan
2019.05.10 Corporate PDF (195KB)
Daiichi Sankyo Announces Changes to Members of the Board and Members of the Audit and Supervisory Board
2019.05.08 R&D PDF (91KB)
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
2019.04.26 Corporate PDF (78KB)
Daiichi Sankyo Announcement Regarding Vaccine Quality Testing Methods
2019.04.26 R&D PDF (100KB)
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
2019.04.25 Corporate PDF (87KB)
Daiichi Sankyo Announces the Sale of Its Nihonbashi Building in Japan
2019.04.15 Products PDF (111KB)
Daiichi Sankyo Launches “Tarlige® Tablets” for Pain Treatment in Japan
2019.04.09 R&D PDF (55KB)
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
2019.04.05 R&D PDF (169KB)
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
2019.04.04 R&D PDF (115KB)
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
2019.03.29 Corporate PDF (98KB)
Daiichi Sankyo Announces Chief Executive Officer (CEO) Change
2019.03.29 Corporate PDF (189KB)
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
2019.03.29 R&D PDF (192KB)
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1
2019.03.27 R&D PDF (113KB)
Daiichi Sankyo Initiates Phase 3 Trial of Mirogabalin in Asian Post-spinal Cord Injury Neuropathic Pain Patients Including Japan
2019.03.25 Products PDF (103KB)
Anti-epilepsy Drug VIMPAT ® for I.V. infusion 200mg Launched in Japan
2019.03.19 Products PDF (136KB)
Daiichi Sankyo Presents Positive Results of the First Randomized, Controlled Trial of Uninterrupted Oral, Once-daily Lixiana® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
2019.03.11 Products PDF (153KB)
Anti-epilepsy Drug VIMPAT® Dry syrup 10% Launched in Japan
2019.02.22 Corporate PDF (89KB)
Daiichi Sankyo Announces Organizational Restructuring Effective April 1, 2019 in Japan
2019.02.22 Corporate PDF (121KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2019.02.06 R&D PDF (88KB)
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
2019.01.31 Corporate PDF (143KB)
Daiichi Sankyo Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant and Company Split (Simple Absorption-type Company Split)
2019.01.15 R&D PDF (271KB)
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
2019.01.10 R&D PDF (178KB)
Daiichi Sankyo, Mitsubishi UFJ Capital and Tokyo Institute of Technology Announce Open Innovation Research on iPS Cell-derived Insulin Producing Cells in Japan
2019.01.08 Products PDF (111KB)
Daiichi Sankyo Announces Marketing Approval in Japan of “Tarlige® Tablets” for Pain Treatment
2019.01.08 Products PDF (91KB)
Daiichi Sankyo Announces Approval of MINNEBRO(TM) Tablets for the Treatment of Hypertension in Japan
2019.01.08 Products PDF (175KB)
Pediatric Dosage and Administration Approved for Anti-epileptic Drug VIMPAT® Tablets 50 mg and 100 mg
2019.01.07 Corporate PDF (74KB)
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.